Get the Stockscreener App
6.77
1.60%
-0.11
Clene Inc stock is traded at $6.77, with a volume of 94,159.
It is down -1.60% in the last 24 hours and down -28.06% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$6.88
Open:
$6.87
24h Volume:
94,159
Relative Volume:
0.50
Market Cap:
$69.96M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-1.5179
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
+17.33%
1M Performance:
-28.06%
6M Performance:
+65.93%
1Y Performance:
+36.49%
1-Day Range:
$6.66
$7.0111
1-Week Range:
$5.42
$7.03
52-Week Range:
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
6.77 | 71.10M | 442.00K | -30.46M | -27.47M | -4.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Nanotechnology Stocks Worth Watching – December 12th - Defense World
Nanotechnology Stocks Worth WatchingDecember 12th - MarketBeat
Promising Nanotechnology Stocks To Add to Your WatchlistDecember 7th - MarketBeat
Best Nanotechnology Stocks To Keep An Eye On – December 10th - Defense World
Nanotechnology Stocks To Consider – December 9th - Defense World
Clene's (CLNN) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Analyst Maintains Buy Rating for CLNN with Stable Price Target | - GuruFocus
Promising Nanotechnology Stocks To Research – December 8th - Defense World
Clene to Present at the Emerging Growth Conference - The Manila Times
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream - Investing News Network
Clene to Present at the Emerging Growth Conference | Associated Press | syndication news - Enidnews.com
Nanotechnology Stocks To Watch TodayDecember 5th - MarketBeat
Exit Recap: How risky is Clene Inc Equity Warrant stock nowPortfolio Gains Summary & Capital Protection Trade Alerts - BỘ NỘI VỤ
Nanotechnology Stocks To Research – December 6th - Defense World
Nanotechnology Stocks To Watch Today – December 5th - Defense World
Clene to seek accelerated approval of ALS drug CNM-Au8 in 2026 - ALS News Today
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Clene (CLNN) and Costco (COST) - The Globe and Mail
Why Clene Inc. (84C0) stock stays resilient2025 Historical Comparison & Entry Point Strategy Guides - Newser
How Clene Inc. (84C0) stock reacts to new regulationsQuarterly Earnings Summary & Reliable Momentum Entry Alerts - Newser
How analysts revise price targets for Clene Inc. (84C0) stock2025 Breakouts & Breakdowns & Growth Focused Stock Pick Reports - Newser
Best Nanotechnology Stocks To Keep An Eye OnDecember 3rd - MarketBeat
Clene (CLNN) Gets a Buy from JonesTrading - The Globe and Mail
Benchmark reiterates Buy rating on Clene stock amid positive biomarker data - Investing.com Canada
Benchmark reiterates Buy rating on Clene stock amid positive biomarker data By Investing.com - Investing.com South Africa
New Data from the NIH-Funded CNM-Au8® Expanded Access Program Provides Support for a Survival Benefit in ALS - Yahoo Finance
Should I hold or sell Clene Inc. Equity Warrant stock in 2025Earnings Summary Report & Free Real-Time Market Sentiment Alerts - Newser
A Look at Clene Inc (CLNN) Shares in the Recent Past Indicates Growth - setenews.com
Why Clene Inc. Equity Warrant stock remains undervaluedBuy Signal & Expert Approved Momentum Trade Ideas - Newser
Clene Inc. (NASDAQ:CLNN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Clene’s (CLNN) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. (CLNN) 12.19% in After-hours: Positive ALS Biomarker Results Boosts Investor Sentiment - Stocks Telegraph
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 - Investing News Network
Caring Brands, Inc. (CABR) 6.25% in After-hours: What’s Driving the Move? - Stocks Telegraph
D. Boral Capital Maintains Buy Rating for Clene (CLNN) | CLNN St - GuruFocus
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Clene (CLNN) Reports Promising Biomarker Results for ALS Treatme - GuruFocus
Clene’s CNM-Au8 Shows Promise in ALS Treatment, Projecting Significant Stock Upside - TipRanks
Clene Updates on CNM-Au8® ALS Program - TipRanks
Clene announces statistically significant ALS biomarker results - marketscreener.com
Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8 - TipRanks
Clene Announces Positive Biomarker Results for CNM-Au8 - TipRanks
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8® - The Manila Times
Clene Inc Announces Significant ALS Biomarker Results - TradingView — Track All Markets
Clene (Nasdaq: CLNN) reports NfL, GFAP drops in ALS as it targets 2026 accelerated NDA - Stock Titan
Will Clene Inc. (84C0) stock see insider accumulation2025 Top Decliners & Daily Risk Controlled Trade Plans - Newser
Nanotechnology Stocks To Watch Now – December 1st - Defense World
Clene Inc. (CLNN) 8.53% in After-hours: Plans Update on CNM-Au8 ALS Program - Stocks Telegraph
Clene to Provide CNM-Au8® ALS Program Update - Investing News Network
Clene Inc. to Provide Update on CNM-Au8 Program in ALS during Investor Call on December 3, 2025 - Quiver Quantitative
Clene (Nasdaq: CLNN) to host Dec. 3 CNM-Au8 ALS program update webcast at 8:30 a.m. ET - Stock Titan
Nanotechnology Stocks To Watch NowDecember 1st - MarketBeat
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Aug 21 '25 |
Sale |
5.34 |
3,401 |
18,161 |
704,591 |
| General Resonance LLC | 10% Owner |
Jun 04 '25 |
Sale |
4.04 |
600 |
2,424 |
707,992 |
| General Resonance LLC | 10% Owner |
Jun 02 '25 |
Sale |
4.12 |
600 |
2,473 |
708,592 |
| General Resonance LLC | 10% Owner |
May 30 '25 |
Sale |
2.80 |
410 |
1,148 |
709,192 |
| General Resonance LLC | 10% Owner |
May 29 '25 |
Sale |
2.73 |
410 |
1,119 |
709,602 |
| General Resonance LLC | 10% Owner |
May 28 '25 |
Sale |
2.60 |
420 |
1,090 |
710,012 |
| General Resonance LLC | 10% Owner |
May 27 '25 |
Sale |
2.45 |
420 |
1,029 |
710,432 |
| General Resonance LLC | 10% Owner |
Mar 19 '25 |
Sale |
4.40 |
1,400 |
6,160 |
710,852 |
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):